Drug
Alks 2680 Dose 1
Alks 2680 Dose 1: highest development phase Phase 3, developed by Alkermes. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Alkermes
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALKS 2680 Dose 1 NCT07455383 | Phase 3 | Narcolepsy Type 1 |
| ALKS 2680 Dose 1 NCT07540897 | Phase 3 | Narcolepsy Type 1 |
| ALKS 2680 Dose 1 NCT07502443 | Phase 3 | Narcolepsy Type 2 |
Latest
No recent events.
Follow Alks 2680 Dose 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.